

GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions

Popianna Tsiortou, Harry Alexopoulos and Marinus C. Dalakas 

Ther Adv Neurol Disord

2021, Vol. 14: 1–17

DOI: 10.1177/
17562864211003486

© The Author(s), 2021.
Article reuse guidelines:
sagepub.com/journals-
permissions

Abstract: Antibodies against glutamic acid decarboxylase (GAD), originally linked to stiff person syndrome (SPS), now denote the “GAD antibody-spectrum disorders” (GAD-SD) that also include autoimmune epilepsy, limbic encephalitis, cerebellar ataxia and nystagmus with overlapping symptomatology highlighting autoimmune neuronal excitability disorders. The reasons for the clinical heterogeneity among GAD-antibody associated syndromes remain still unsettled, implicating variable susceptibility of GABAergic neurons to anti-GAD or other still unidentified autoantibodies. Although anti-GAD antibody titers do not correlate with clinical severity, very high serum titers, often associated with intrathecal synthesis of anti-GAD-specific IgG, point to *in-situ* effects of GAD or related autoantibodies within the central nervous system. It remains, however, uncertain what drives these antibodies, why they persist and whether they are disease markers or have pathogenic potential. The review, focused on these concerns, describes the widened clinical manifestations and overlapping features of all GAD-SD; addresses the importance of GAD antibody titers and potential significance of GAD epitopes; summarizes the biologic basis of autoimmune hyperexcitability; highlights the electrophysiological basis of reciprocal inhibition in muscle stiffness; and provides practical guidelines on symptomatic therapies with gamma-aminobutyric acid-enhancing drugs or various immunotherapies.

Keywords: autoantibodies, cerebellar ataxia, encephalitis, GAD autoimmunity, hyperexcitability, stiff person syndrome

Received: 23 February 2021; revised manuscript accepted: 27 February 2021.

Introduction

GAD (glutamic acid decarboxylase) is a pyridoxal 5'-phosphate-dependent enzyme, widely expressed within the central nervous system and pancreatic β -cells, that catalyzes the conversion of the excitatory neurotransmitter l-glutamate to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).¹ Autoantibodies against GAD were first detected in 1988 in a patient with stiff person syndrome (SPS), epilepsy and type-1 diabetes mellitus (DM-1), pointing out to an immunological connection between SPS, DM-1 and epilepsy and highlighting since then that disruption of GABAergic neurotransmission results in neuronal excitability.² Over the ensuing years, anti-GAD antibodies have been also connected with other

autoimmune neurological diseases associated with neuronal excitability that now comprise the “GAD antibody-spectrum disorders” (GAD-SDs) and include SPS, autoimmune epilepsy, cerebellar ataxia, limbic encephalitis, myoclonus and nystagmus.³

As the clinical spectrum of GAD-SD is now widened and their overlapping symptomatology more clearly recognized, a number of puzzling clinical connections, diagnostic dilemmas and pathogenic mechanisms have emerged. New information about GAD epitopes and the importance of GAD titers has further strengthened their specificity in defining GAD-SD. While low GAD antibody titers directed at different epitopes are seen

Correspondence to:
Marinus C. Dalakas
Department of Neurology,
Thomas Jefferson
University, 900 Walnut
Street, Philadelphia,
PA 19107, USA;
Neuroimmunology Unit,
National and Kapodistrian
University of Athens,
Athens, Greece
marinos.dalakas@jefferson.edu;
mdalakas@med.uoa.gr
Popianna Tsiortou
Harry Alexopoulos
Neuroimmunology
Unit, Department of
Pathophysiology, Faculty
of Medicine, National and
Kapodistrian University of
Athens, Athens, Greece

in 80% of patients with DM-1,⁴ and up to 30% of patients with GAD-SD also have DM-1, only patients with typical GAD-SD neurological syndromes exhibit very high titers. The paper aims to describe the evolved clinical manifestations of GAD-SD; discuss why antibody titers matter in diagnosis and immunopathogenesis; highlight how GABAergic neurotransmission results in such diverse clinical phenomena with reciprocal inhibition and muscle stiffness; and summarize the best therapeutic options to treat autoimmune neuronal excitability. Considering that SPS is not as rare as has been thought, but still misdiagnosed, based on the large number of patients seen in our clinic, the review is hoped to increase the awareness of these syndromes for practicing neurologists and facilitate early diagnosis and prompt therapy initiation.

Clinical manifestations

SPS

SPS, first described by Moersch and Woltman in 1956,⁵ is the commonest and most characteristic clinical subtype of GAD-SD. Although its precise frequency is unclear, based on the large number of patients referred to us in the last 30 years and having the opportunity to screen, examine, treat and follow many such patients in-person, rather than from chart reviews and retrospective data collection, we believe it is a fascinating disorder, more common than previously thought, but still under-recognized or misdiagnosed. SPS is twice as common in women than men, frequently represented among African-American women, with an average age of onset at around 30–35 years.^{6,7} Patients typically present with muscle spasms and stiffness, concurrently in the thoracolumbar paraspinal and abdominal muscles, resulting in difficulties turning and bending, and progressive muscle rigidity with hyperreflexia and spasms, mainly in the truncal and proximal leg muscles.⁸ Severe truncal stiffness resembles a “statue” or a “freezing”-like appearance and patients often describe that they walk like a “tin-man”. They often have an accompanying severe anxiety, often misdiagnosed as a primary anxiety disorder, and task-specific phobias⁹ that include fear of walking and falling. Symptoms of muscle spasms and stiffness can be precipitated by unexpected stimuli, including sounds, like a phone ringing or a siren, sudden touches or emotional upset. In some cases these events can cause severe and continuous painful

spasms, along with stiffness in the thoracic muscles with breathing difficulties, tachycardia and hyperhidrosis, a condition we have labeled “status spasticus”, requiring emergency admission for intravenous diazepam.¹⁰ Electrophysiological studies have revealed continuous activity of motor unit firing at rest, confirming that stiffness is caused by co-contractions of agonist and antagonist muscles.^{11–13} Normal physiology is governed by reciprocal inhibition, which means that when one muscle (i.e. biceps) contracts, its antagonist (i.e. triceps) is automatically inhibited. Stimulated gamma neurons of the agonist muscle send information to the spindles to contract, while the antagonist’s gamma neurons do not discharge due to inhibition of GABA interneurons (Figure 1). In pathologic situations of impaired GABAergic neurotransmission, as occurs in SPS due to reduced GABA from the cerebral motor pathways, the gamma motor neurons discharge continuously because inhibitory signals are inhibited, resulting in bursting overstimulation of the muscle spindles expressed as simultaneous hypercontraction of both agonist and antagonist muscles (Figure 1). This is clinically manifested with muscle rigidity and stiffness and electrophysiologically as continuous motor unit activity in agonist and antagonist muscles. Up to 80% of SPS patients have autoantibodies against GAD, the rate-limiting enzyme for GABA synthesis.¹⁴ These antibodies may interfere *in vitro* with GABA production and *in vivo* with the entire GABAergic system,^{15,16} explaining the unbalanced neurotransmission and the ensuing enhanced hyperexcitability expressed as spasms and stiffness. Since GAD is also expressed in pancreatic cells and patients with DM-1 have low-titer anti-GAD antibodies, as discussed below, up to 35% of SPS patients may also have DM-1 along with and other autoimmune diseases, such as vitiligo, pernicious anemia, celiac disease or thyroiditis.^{4,17,18}

The diagnostic criteria for SPS, as revised in 2009,¹⁷ include: (1) stiffness of the axial muscles, particularly the abdominal and thoraco-lumbar paraspinals, leading to hyperlordosis; (2) superimposed painful spasms triggered by unexpected tactile or auditory stimuli; (3) severe anxiety with task-specific phobias especially in anticipation of physically challenging tasks; (4) electromyographic evidence of continuous motor unit activity of agonist and antagonist muscles; (5) absence of other neurological findings that may suggest an alternative diagnosis; and (6) highly positive GAD-antibody titers by




Figure 1. Reciprocal inhibition and stiffness generation in stiff person syndrome patients.

(a) Normal function: when one muscle is contracted, its antagonist is automatically inhibited. Afferent Ia sensory neuron fires, bringing information to the spinal cord, and stimulates the gamma neurons. Then, the gamma-motor neurons of the agonist muscle send signals to the spindle to contract [1], while the gamma motor neurons of the antagonist muscle do not discharge (X) due to inhibition of GABA interneuron [3]. As a result, the alpha-motor neuron of antagonist stretches (relaxes) the muscle [2] (interneuron: releases inhibitory mediators).

(b) Pathology: if the motor neuron is continuously firing signals, while there is no inhibition of the GABA interneuron to the antagonist muscle, the whole muscle will continuously be stimulated and will become hypertonic (spastic), without the ability to stretch (relax), due to concurrent contraction of the agonist and the antagonist muscles, as happens in stiff person syndrome that presents with stiffness and hyperexcitability.

immunocytochemistry, Western blot, enzyme linked immunosorbent assay (ELISA) or radioimmunoassay. Although these criteria best describe “classic or typical SPS”, some patients with positive anti-GAD antibodies may not exhibit all the aforementioned symptomatology.

In our longitudinal study of 57 anti-GAD-positive SPS patients, which represents the largest clinical series of personally examined patients every 6 months for a two-year period to assess disease progression, the most common initial symptom was the insidious onset of proximal leg stiffness followed by rigidity in the lumbosacral paraspinals, thoracic and abdominal muscles. Axial muscle stiffness (truncal and proximal legs), lumbar hyperlordosis and impaired gait were first signs in 68% of these patients with 28% of them also having various degrees of facial muscle stiffness.¹⁹ About 15% of the patients with typical SPS symptomatology also had ataxia, dysarthria and

dysphagia, overlapping with the cerebellar variant, as described below, an important distinction because these patient subsets do not fully respond to immunotherapies.²⁰ Exaggerated reaction to various external stimuli and “startle response” were present in all patients except two. Marked anxiety related to unprotected falls or in anticipation of physically challenging situations was seen in 52 of 57 patients; 21 patients experienced chronic anxiety combined with intermittently depressed mood. Simple phobias, such as fear of walking in open and crowded places, crossing a street or taking escalators, were reported by more than 10% of patients with several also having task-related phobias, such as fear of public speaking. Most patients had been misdiagnosed with conversion or functional disorder because their falls were attributed to avoidant behavior and heightened mental anticipation. Other common misdiagnoses were myelopathies, dystonias or Parkinsonism. Many patients reported muscle

SPS antibodies




Figure 2. Autoantigenic targets associated with the Central Nervous System inhibitory synapses in patients with stiff person syndrome.

The pre-synaptic antigens are GAD (1), the enzyme that synthesizes GABA, the main inhibitory neurotransmitter, and amphiphysin (2), a synaptic vesicle protein responsible for endocytosis of plasma membranes following GABA release. Post-synaptically, the main targets are GABA-A Receptor Associated Protein (GABARAP) (3), gephyrin (4), a tubulin-binding protein needed for clustering both GABA-A (5) and glycine receptors (6). The most common antigen in stiff person syndrome is GAD followed by glycine receptor [vesicular inhibitory amino acid transporter; VIAAT]. Modified from Dalakas.¹¹⁸ GABA, gamma-aminobutyric acid; GAD, glutamic acid decarboxylase.

pain along with painful spasms and some had been on narcotics.

Although some patients may manifest concurrent neuropsychiatric symptomatology that when prominent necessitates the need for psychiatric advice, others have been labeled as having a functional disorder. Formal neuropsychiatric testing in 10 consecutive patients seen at the (National Institutes of Health NIH) did not meet Diagnostic and Statistical Manual for Mental Disorders IV criteria for phobic disorder.⁹ It was felt by our mental health colleagues at the National Institutes of Mental Health (NIMH) that the patients perceived their fears and anxiety as realistic, arising from

the possibility of falls caused by SPS.¹⁰ This still, however, remains a puzzling interpretation since we do not see such phenomena in other neurological disorders that present with weakness and falls.

Apart from the antibodies against GAD, other antibodies may also be positive in patients with SPS and hyperexcitability syndromes (Figure 2). We had found antibodies against GABA-A receptor-associated protein in about 70% of the patients,¹⁹ but these findings have not been replicated. Another autoantibody found in 10–15% of SPS patients is against glycine- α 1 receptor (GlyR), a key inhibitory neurotransmitter. Anti-GlyRa1 antibodies, first described in progressive encephalomyelitis with

rigidity and myoclonus (PERM),^{21,22} as discussed below, may be pathogenic as they recognize extracellular epitopes of the receptor expressed in the spinal cord, brainstem and cerebellum. Low-titer autoantibodies against GABAA receptor are also found in 10% of patients with SPS, cerebellar ataxia, epilepsy or encephalitis.³ In about 5% of patients, SPS can be paraneoplastic, associated with antibodies against amphiphysin^{23,24} and in a single case against gephyrin.²⁵ Apart from GlyR all targeted antigens are predominantly cytoplasmic and it remains to be determined whether they can transiently exhibit an extracellular domain during neurotransmission and exocytosis that may account for pathogenicity.²⁶

Cerebellar ataxia

Anti-GAD antibody-associated cerebellar ataxia is the second most frequently encountered GAD-related neurological disorder within the GADSDs. It affects more women than men, often with comorbid DM1 or polyendocrine autoimmunity.^{27–31} These patients exhibit gait and limb ataxia, nystagmus, severe dysarthria, dysphagia and oculomotor dysfunction, most often overlapping with the typical SPS symptomatology that worsens the overall clinical picture.³² CSF analysis may show oligoclonal bands, without protein elevation, and intrathecal anti-GAD antibody synthesis.^{20,28} Although in an old prospective study of 320 patients with sporadic cerebellar ataxia only six (2%) had GAD antibodies,³³ the frequency is probably higher today.

Whether the antibodies play a role in the pathogenesis of cerebellar ataxias is unclear.³⁴ Recent studies showed that a monoclonal GAD65Ab interferes with GABAergic neurotransmission in brain slice preparations and *in vivo* elicits in animals neurophysiological and behavioral effects mimicking cerebellar ataxias.³⁵ Intracerebellar administration of IgGs from CSF of patients with GAD-associated cerebellar ataxia impairs cerebellar modulation of motor control and contributes to lack of coordination.^{36–40} The anti-GAD antibodies seem to act on nerve terminals of GABAergic interneurons depressing the release of GABA, resulting in hyperexcitability and eventually loss of Purkinje cells with diffuse proliferation of Bergmann glia.^{41,42} Furthermore, a human monoclonal GAD65Ab elicits some pathogenic effects resembling those induced by cerebrospinal fluid (CSF) IgGs.^{35,39} These patients may have overlapping clinical manifestations with epilepsy and SPS.⁴³ The

magnetic resonance imaging (MRI) of cerebellar ataxia patients is normal with rare instances of mild cerebellar atrophy,²⁸ implying a functional blockade rather than a destructive process, hence the need to pursue immunotherapies.^{17,44}

Autoimmune epilepsy

GAD antibodies were first associated with drug refractory temporal lobe epilepsy in 1998.⁴⁵ It is considered the third most common GAD65 neurological autoimmunity, and probably one of the most common causes of autoimmune epilepsy.⁴⁶ In early retrospective studies of 200 cases, GAD-antibodies were most frequent in patients with chronic pharmaco-resistant epilepsy, who often presented with temporal lobe epilepsy, *epilepsia partialis continua* or refractory convulsive and non-convulsive status epilepticus,^{47–49} without inflammatory markers in the CSF or MRI but higher frequency of autoimmune comorbidities.^{48,49}

In other retrospective series, anti-GAD antibodies were detected in 22% of patients with various epilepsies and concurrent autoimmune associations.⁵⁰ In a cohort of 233 patients with all types of epilepsy, the percentage of GAD-Abs was only 2.3%,⁵¹ but when dissecting out the patients with focal epilepsy, GAD-Abs were present in 16% of all cases,⁵² while among patients with temporal lobe epilepsy the percentage was up to 21.7%.⁵³ In a series of 1510 epileptic patients, three had musicogenic reflex seizures (MRSs) with two of them having GAD-associated epilepsy.⁵⁴ MRSs have also been reported in a patient with SPS comorbidity.⁵⁵ Although this clinical manifestation is extremely rare, MRS may be a distinctive type of epilepsy highlighted by anti-GAD antibodies, necessitating the need to test for GAD antibodies in all suspected MRS cases, even with normal structural MRI.⁵⁴ Among 13 children with epilepsy and mean age of 6 years (range 1–13 years), seven with suspected autoimmune epilepsy were positive for neuronal surface antibodies (N-Methyl-D-Aspartate Receptors in 3, Voltage Gated Potassium Channel-complex in one and GAD in another). Immunotherapy in nine neuronal surface antibody-positive cases was reported effective.⁵⁶

Cytotoxic T lymphocytes have been found in histological preparations of temporomesial tissue from patients with pharmaco-resistant epilepsy associated with GAD antibodies who underwent temporal lobectomy.⁵⁷ These T cells may release perforin

and granzyme, leading to necrosis, apoptosis or electrical silencing of the respective neurons.⁵⁸ It has been suggested on these findings that epilepsy may be caused by potentially neurotoxic CD8⁺ cells against GABAergic interneurons.⁵⁹

The anti-GAD antibodies, by inhibiting GABAergic pathways, may result in hyperexcitability, which can explain epileptogenesis. The intrathecal synthesis of GAD antibodies has been proposed to suggest degeneration of GABAergic neurons and release of cytoplasmic proteins into the CSF, leading to an antibody-mediated immune response.² Such a humoral response may potentially inhibit the function of GAD, decrease the conversion of glutamate to GABA and eventually result in excessive excitatory neurotransmission that lowers the seizure threshold, contributing to manifestation of drug-resistant epilepsy.⁶⁰ At least 5% of SPS patients have seizures,^{61,62} although in our experience the epilepsy in SPS is not refractory but rather easily controlled. On the other hand, only a small number of patients with GAD-associated epilepsy seem to respond to routine immunomodulating therapies, requiring more aggressive immunosuppressants.⁵⁹

Limbic encephalitis

Autoimmune limbic encephalitis with anti-GAD antibodies clinically presents like the classic autoimmune or paraneoplastic limbic encephalitis,⁶³ with impaired working memory, psychiatric symptoms, seizures or altered level of consciousness.⁶⁴ In some patients there are oligoclonal bands in the CSF and intrathecal synthesis of GAD-Abs⁶⁵ but the causative role of GAD antibodies remains unclear.

PERM

PERM, described the same year as SPS by Campbell and Garland, was considered as an SPS-spectrum disorder.⁶⁶ PERM is now a distinct syndrome characterized by muscle stiffness, spasms, myoclonus and brainstem dysfunction with oculomotor abnormalities, dysphagia, gait ataxia prominent autonomic involvement and depressed level of consciousness.⁶⁷ It seems equally present in men and women although in our small series all patients were men. The hallmark of this disorder is the presence of anti-GlyR antibodies. As mentioned earlier, up to 15% of SPS patients with anti-GAD antibodies also harbor low titers of anti-GlyR-Abs.^{68–70}

An underlying tumor, especially thymoma or lymphoma, can be detected in about 20% of PERM patients.⁷¹ Another autoantibody detected in four patients with PERM is anti-DPPX,⁶² characterized by diverse symptomatology including prominent gastrointestinal manifestations, seizures, encephalopathy, sleep disturbance and dysautonomia. Limited histological data on PERM has demonstrated inflammatory and microglial changes and cell loss in the pons, medulla, cerebellum, spinal cord and autonomic ganglia.⁸ Some PERM patients had increased T2 fluid-attenuated inversion recovery signal of spinal cord and brainstem on MRI.⁶⁷ In our small series, PERM is highly responsive to immunotherapies, especially if started early.

Nystagmus and abnormal eye movements

Isolated oculomotor dysfunction, characterized mainly by downbeat nystagmus and saccadic intrusions/oscillations but rarely ophthalmoparesis, can be also associated with anti-GAD antibodies. In our experience, oculomotor dysfunction is not unusual among all GAD-positive patients with SPS, especially those with cerebellar ataxia.^{72–75} The most common isolated GAD-positive oculomotor dysfunction is persistent horizontal or downbeat nystagmus, presumably related to excitability of vestibular nuclei driving the motor neurons of the ocular muscles, resulting in upward slow phase with quick compensatory downward phase or horizontal saccades.^{73,76,77} Within the GAD-SDs, opsoclonus and myoclonus have been also observed.^{78,79}

The importance of GAD antibody titers in the diagnosis of SPS-SD and distinction from DM-1

The importance of high GAD titers in connection with true neurological syndromes, compared with atypical or non-specific entities and DM-1, has been recently re-emphasized, pointing out that anti-GAD antibody titers do matter for diagnosis, even though their pathogenicity is still unclear. Patients with the described typical neurological diseases within the GAD-SDs normally have very high anti-GAD antibody titers compared with moderate–low titers in atypical syndromes and very low titers in DM-1.⁷⁴ Several assays are being used to detect anti-GAD antibodies, generating at times confusion in clinical practice, including quantitative radio-immunoassays (RIAs) and ELISAs.^{27,61,80} These assays, initially developed

to detect the low titers of GAD antibodies in DM-1 patients, require adaptations with serial serum dilutions to ensure the accurate detection of high titers characteristic of SPS-SD patients. Other qualitative assays such as tissue immunohistochemistry, cell-based assays or line blots are mostly useful to detect structural epitopes of GAD65 antibodies.

Depending on the laboratory and the method used, reference values may be expressed in different units. A major US clinical laboratory uses RIA and defines high titers as $>$ or $=20$ nmol/L.^{81,82} According to their experience, these titers are found in classic SPS (93% positive) and in related autoimmune neurologic disorders, while values in patients who have DM-1 without a polyendocrine or autoimmune neurologic syndrome usually have titers $<$ or $=20$ nmol/L. Other US and European laboratories use ELISAs, where the cutoff for positivity is >5 IU/mL. According to various clinical studies in SPS patients, titers are considered high when they are above 10,000 IU/mL.⁷⁴ The same applies to our own laboratory where we use ELISA. Titers within the range of 5–2000 IU/mL are seen in DM-1; only titers $>10,000$ IU/mL are associated with a neurologic disorder. In a recent study, the significance of serum anti-GAD65 antibody titers in connection with true neurological disease was re-confirmed by setting a cutoff value of 10,000 IU/mL in ELISA based on their specificity in concurrent testing by immunohistochemistry and cell-based assay. High ($>10,000$ IU/mL) titers conferred specificity for an autoimmune neurological disease in 94% of the patients, including SPS, cerebellar ataxia, chronic epilepsy, limbic encephalitis, or overlapping conditions; in contrast, lower concentration antibodies were seen in a broader spectrum of heterogeneous disorders.⁸³ The high titers were also associated with measurable anti-GAD antibodies in the CSF.

Collectively, the practicing neurologists need to be aware that anti-GAD antibody titers do matter: if high ($>10,000$ IU/mL), they are diagnostic for a true GAD-SD, necessitating immunotherapy; lower ($<10,000$ IU/mL) titers are associated with atypical or non-specific neurological disorders requiring further investigation, whereas very low titers (<2000 IU) are typically seen in DM-1 or are of unclear significance.⁷⁴ Importantly, GAD-Abs can also be detected within the various IVIg preparations and anti-GAD antibodies can

be detected in patients receiving IVIg.⁸⁴ Most importantly, there is no association between GAD-Ab titer and disease severity or response to therapy without significant titer reduction after immunotherapies with either IVIg or rituximab based on two controlled studies we have performed.^{85,86}

Intrathecal synthesis of GAD antibodies

There is strong evidence that in SPS, as well as in patients with other GAD-SDs, there is intrathecal synthesis of GAD antibodies. In a pivotal study, using the Link's formula, the ratio of GAD antibody concentration in the CSF to that in the serum was divided by the ratio of albumin concentration in the CSF to that in the serum; on this basis, values >1 are indicative of robust intrathecal synthesis.⁵⁷ In clinical practice, when the serum GAD antibody titers are above 10,000 IU/mL, GAD antibodies are also detected in the CSF⁷⁸ and, in these circumstances, a diagnostic lumbar puncture may not be necessary, especially in SPS patients where the stiffness in the lumbar paraspinals requires a radiology-guided puncture.

The demonstration, however, of intrathecal GAD antibody synthesis comprises the strongest evidence linking a neurological syndrome to autoimmunity, as suggested.⁸⁷ In clinical practice, testing the CSF for GAD antibodies is helpful in patients with serum titers below 10,000 IU/mL and in patients with seronegative GAD-spectrum disorder, especially those with encephalitis, and in patients with a seemingly functional disorder resembling SPS symptomatology.

GAD epitopes and their potential significance

GAD exists in two isoforms, GAD65 and GAD67, each encoded by a different gene, *GAD1* and *GAD2*, located in chromosomes 2q31.1 and 10p12, respectively.⁸⁸ GAD65 represents the membrane form of the enzyme. It is found in synaptic vesicles in the nerve endings and it is mostly utilized under circumstances where there is an urgent need of GABA synthesis and release.^{89,90} GAD67 represents the soluble form, it is abundant in the cytoplasm and it is implicated in functions such as synaptogenesis, but not neurotransmission. The two isoforms are divided according to their linear sequence into three functional domains:

Table 1. Diagnostic work-up.

Clinical evaluation	Electrophysiology	Immunological studies	Neuropsychiatric examination
<ul style="list-style-type: none"> • Axial rigidity • Episodic spasms often triggered by unexpected external stimuli or emotional upset • No other neurological diseases that could account for stiffness 	Continuous co-contraction of agonist and antagonist muscles with inability to relax	Sera and CSF (when applied) are tested by ELISA and CBAs for relevant autoantibodies: <ul style="list-style-type: none"> • Anti-GAD • Anti-GlyR • Anti-GABAA receptor • Anti-amphiphysin • Anti-gephyrin GAD seronegative patients need to be examined carefully as they may have a functional disorder	Structured interviews, whenever clinically required, for the Diagnostic and Statistical Manual for Mental Disorders (DSM-IV) Axis I (SCID-I/P) to explore the origin of anxiety and phobic symptoms

CBA, Cell-based Assay; CSF, cerebrospinal fluid; ELISA, enzyme linked immunosorbent assay; GABAA, gamma-aminobutyric acid A; GAD, glutamic acid decarboxylase; GlyR, glycine- α 1 receptor.

an amino(N)-terminal domain, amino acids-aa 1-188 (1-197); a middle PLP-binding domain, where the catalytic center of the enzyme resides, aa 189-464 (198-473), and a carboxy (C)-terminal domain, aa465-585 (474-594).⁹¹ The isoforms show an overall similarity within the middle and C-terminal domains, having 74% identity, while the N-terminals have 25%.⁴ More specifically, patients with SPS and cerebellar ataxia show strong immunoreactivity to b78 epitopes, whereas those with DM-1 recognize more commonly the b96.11 epitopes.^{87,92,93} Antibodies against b78 inhibit the enzymatic activity of GAD and provoke depression in the inhibitory synapsis in rat cerebellar slices, whereas these events are not observed with antibodies against the b96.11 epitope.³⁵ Patients with DM-1 harbor antibodies directed against conformational epitopes exclusively located in the PLP- and C-terminals domains.^{94,95} In contrast, patients with SPS predominantly recognize linear epitopes in all three domains^{96,97} and in the first 100aa that constitute the regulatory sequence in the N-terminal domain of GAD65 and does not react with DM-1 sera.^{92,98-101} The GAD-Abs therefore in SPS exhibit a different epitope pattern of antibody reactivity with distinct biological effects, compared with DM-1.

Whether different epitope patterns exist among GAD-related syndromes is unclear. In one study, GAD-Abs from patients with limbic encephalitis were more likely to recognize epitopes in the N-terminal domain, compared with those with SPS, cerebellar ataxia or epilepsy, with the latter showing more reactivity to the C-terminal domain of the enzyme.^{35,102} In our study, however, of 27

patients with diverse GAD-related syndromes, no differences in epitope specificities were found except in three patients with epilepsy.¹⁰³ Accordingly, the current data cannot explain the diverse clinical presentation based on different epitope binding patterns.

Diagnostic work-up and concerns in diagnosing GAD-negative SPS

The diagnostic work-up for SPS includes the clinical criteria mentioned earlier in conjunction with electrophysiological data, and relevant autoantibody seropositivity mainly highlighted by anti-GAD with cutoff titers >10.000 IU/mL by ELISA, as mentioned earlier (Table 1).^{15,104} The main difficulty remains the seronegative SPS that represents close to 20% of patients with seemingly clinical SPS. Considering that functional components can co-exist in some patients with high-GAD titers, the main concern in practice is to ensure that patients with seronegative SPS do not have a functional disorder or another neurological disease mimicking SPS. Adherence to strict clinical criteria, neurophysiologic testing and neuropsychiatric assessment, if needed, are essential. Although an empirical trial with diazepam is often used, it does not ensure diagnostic accuracy because it cannot differentiate an organic from a functional disorder.

Pathogenesis of GAD-SD and biologic basis of autoimmune hyperexcitability

The pathogenesis of GAD-associated syndromes is still uncertain. Despite the key role of

autoantibodies in defining a rather heterogeneous group of overlapping disorders, it is not yet clear whether GAD antibodies are pathogenic or markers of aberrantly activated innate and acquired immunity.

Rats treated intracerebroventricularly with SPS-IgG showed a stiffness-like behavior, a decline of motor function as measured by time on the Rotarod test and a decrease in forelimb grip strength as compared with control IgG-infused rats. Additional studies of passive transfer of GAD-Abs from patients into rats or mice have shown continuous motor activity with repetitive muscle discharges and abnormally enhanced reflexes with increased excitability of anterior horn cells.^{38,39,105} Whether these effects are related to anti-GAD or other antibodies directed at different synaptic antigens is unclear. On the other hand, diffusion of IgG and quantification of enhanced green fluorescent protein-labeled neurons after SPS IgG injection into mice did not generate any symptoms.¹⁰⁶ Furthermore, stereotactic injection of GAD-Abs into the hippocampus of rats *in vivo* did not alter spontaneous and evoked GABAergic synaptic transmission.^{107,108} In contrast to anti-GAD antibodies, animals treated intraperitoneally¹⁰⁹ or intrathecally¹¹⁰ with IgG anti-amphiphysin Abs have exhibited stiffness-like behavior.

Equally controversial are the data from experiments conducted in cultured neurons. Hippocampal cultured neurons treated with sera from epileptic GAD-positive patients showed an increase of post-synaptic inhibitory potentials compared with negative controls.¹¹¹ Further, when rat cerebellar slices were exposed to serum or CSF from patients with SPS or cerebellar ataxia, a decrease of post-synaptic inhibitory currents of Purkinje cells was observed, compared with GAD-negative sera from ataxic patients.^{72,112,113} Some studies have also shown epitope-dependent pathogenic actions of GAD-Abs in histological brain sections and *in vivo* preparations,^{35,106,114} whereas others showed lack of internalization into hippocampal cultured rat neurons³ (Table 2). It remains, however, unclear how GAD-Abs can cause the GABAergic dysfunction in SPS if not internalizing into neurons. The possibility that antigens during synaptic transmission transiently expose extracellular epitopes, recognized by the immune system, remains hypothetical.

Circulating GAD-reactive B cells that can differentiate into antibody producing cells have been also detected in the peripheral blood and bone marrow of patients with GAD-Ab associated neurological syndromes. Interestingly, the presence of GAD was not required for induction of GAD-antibody producing cells and GAD-Ab production by stimulated peripheral blood cells did not correlate with GAD-Ab serum levels, suggesting an additional source of GAD-Abs. This study implied that targeting both memory B cells (i.e. with rituximab) and plasma cells (i.e. with bortezomib) might be a potential treatment option.¹¹⁵

Anti-GAD antibodies are typically found in the peripheral blood and in lower levels in the CSF.¹⁵ GAD-Abs in CSF on occasion can be detected as monoclonal bands, suggesting that only a fraction of the whole anti-GAD response occurs in the CNS and that the intrathecal production of GAD-Abs could facilitate their access to relevant neuronal autoantigens. Interestingly, the intrathecal monoclonal IgGs are reactive to GAD65.^{3,4} The role of B cells remains, however, unclear. The statistically negative controlled study with rituximab (see below) cannot be interpreted to suggest that B cell suppression and antibody production may not be critical factors, because the study had an impressive effect in some patients but it was statistically negative due to a strong placebo effect. The same may also apply to the lack of correlation of antibodies titers to disease severity. Interestingly, it has been observed that mice possessing a monoclonal GAD65 specific CD4⁺ T cell population develop a lethal encephalomyelitis-like disease in the absence of any other T cells or B cells.¹¹⁶

Therapeutic approaches

SPS patients experience severe anxiety and depression due to phobias of sustaining falls or inability in completing even simple physical tasks. Patients with significant symptoms that do not improve concurrently with the physical symptomatology need clinical and psychological support both at home and at work. Their phobias often lead to depression, or at times addiction to drugs such as benzodiazepines or narcotics, highlighting the need for multifactorial care.

For SPS and GAD-SD, two strategies of treatment are implemented: symptomatic (anti-spasmodic) or immunologic¹¹⁷ interventions either independently

Table 2. Experimental animal models of glutamic acid decarboxylase antibody-spectrum disorder.

Experimental approach	Sample	Clinical manifestation	Result	Reference
(a) Stereotactical injection into rats' hippocampi	CSF	Focal epilepsy due to LE	NO changes on GABAergic transmission	Hackert <i>et al.</i> ¹⁰⁷
(b) Intraperitoneal injection into transgenic mice	IgG	PERM and SPS	NO differences in behavioral tests NO loss of GAD-EGFP neurons	Chang <i>et al.</i> ¹⁰⁶
(c) Epitope specificity: monoclonal GAD Ab in cerebellar slices and mice	Sera	CA, SPS, LE, T1D	b78 inhibits GAD enzyme activity	Manto <i>et al.</i> ³⁵
(d) Whole-cell patch-clamp technique on cerebellar slices	IgG from CSF	CA	Effects presynaptically with suppression of GABAergic transmission	Mitoma <i>et al.</i> , ¹¹³ Takenoshita <i>et al.</i> , ⁷² Ishida <i>et al.</i> ¹¹²
(e) Whole-cell patch-clamp technique on hippocampal slices	Sera	Epilepsy, T1D	Increase of frequency of IPSPs	Vianello <i>et al.</i> ¹¹¹
(f) GAD-Abs in rat cerebellar slices	Sera, CSF	SPS, T1D, autoimmune PS	SPS: reduction of GABA production T1D/PS: NO differences in enzyme's activity	Dinkel <i>et al.</i> ¹⁵
(g) Intracerebellar injection in rats	IgG from sera	SPS, CA, paraneoplastic CA (GAD-), T1D	GAD ⁺ : altered cerebellar activity, impaired learning, muscle discharges, abnormal reflexes GAD ⁻ : NO effect	Manto <i>et al.</i> ³⁸
(h) Passive transfer of Abs in mice	GAD-Abs	-	Loss of GAD-EGFP neurons NO behavioral changes	Chang <i>et al.</i> ¹⁰⁷
(i) Intraventricular (i.c.v.) and intrathecal (i.th) injection	IgG	SPS	i.c.v.: stiffness-like behavior, impaired walking ability, sensorimotor dysfunction, normal anxiety test i.th: NO motor symptoms; normal spinal transmission	Hansen <i>et al.</i> ¹⁰⁵

CA, cerebellar ataxia; CSF, cerebrospinal fluid; EGFP, enhanced green fluorescent protein; GABA, gamma-aminobutyric acid; GAD, glutamic acid decarboxylase; IPSP, Inhibitory Postsynaptic Potentials; LE, Limbic encephalitis; PERM, progressive encephalomyelitis with rigidity and myoclonus; PS, polyendocrine syndrome; SPS, stiff person syndrome; T1D, DM-1.

or in combination, depending on symptom severity (Table 3). Symptomatic relief is often achieved with agents that enhance GABAergic transmission, such as benzodiazepines, which diminish spasms and stiffness, especially those triggered by emotional factors. The first therapeutic option is diazepam, a GABAA agonist. This drug can help most patients, although the high doses sometimes required cannot be tolerated and may lead to addiction. Other similar compounds include clonazepam, alprazolam, lorazepam and temazepam. The

second category of drugs used as anti-spasticity agents are GABAB agonists. Because of better tolerance and no addiction potential, we have now started using these agents as first line therapy in lieu of benzodiazepines. The most effective among them is baclofen, to the point of now using it as first in order. Sometimes high doses (up to 60mg) are required to induce meaningful improvement, resulting in some cognitive issues. Antiepileptic drugs that enhance the brain's GABAergic transmission also improve symptomatology, either alone

Table 3. Therapies of stiff person syndrome.

Symptomatic			Immunologic	
Drug category	Agents	Effect	Immunomodulating	Effect
GABAA agonists	Diazepam Chlonazepam Alprazepam Lorazepam Temazepam	Enhance GABAergic transmission Can help most patients High doses: not tolerated	IVIg	The only proven immunomodulatory therapy: beneficial in SPS
GABAB agonists	Baclofen	Antispasticity drug High doses may cause cognitive effects	Plasmapheresis	Not routinely used: Inconsistent and transient benefits
α 2 adrenergic receptor	Tizanidine	Muscle relaxant	Corticosteroids	Mostly ineffective
Ca ²⁺ inhibitor	Dantrolene	Muscle relaxant	Immunosuppressants	
Anti-epileptic drugs	Gabapentin Vigabartin Tiagabine Leveritacetam	Inhibition of GABA transmission	Azathioprine Methotrexate Cyclophosphamide Cellcept Rituximab HSMT	Mostly ineffective Rituximab, although statistically insignificant against placebo, may have impressive benefits in some patients

GABA, gamma-aminobutyric acid; HSMT, Hematopoietic Stem Cell Transplantation; IVIg, intravenous immunoglobulin; SPS, stiff person syndrome.

or in conjunction with baclofen and benzodiazepines. In our experience, the most helpful agents in this family are gabapentin and vigabatrin, which act by inhibiting GABA-transaminase. Others include tiagabine, an inhibitor of GABA re-uptake, and levetiracetam, which facilitates inhibition of GABAergic transmission. Tizanidine, a centrally acting α 2 adrenergic receptor, and dantrolene, a muscle relaxant, can also help.

If the above agents do not offer a satisfactory benefit, we proceed to immunotherapy. The most widely used agent in this category is intravenous immunoglobulin (IVIg) after its proven efficacy. In a randomized, double-blinded, placebo-controlled crossover trial we conducted in GAD-positive SPS patients, IVIg resulted in significant improvements in objective stiffness parameters and activities of daily living.⁶¹ The duration of efficacy after each monthly IVIg infusion ranges from 4 to 12 weeks in most patients. IVIg remains the only immunomodulatory therapy with proven benefit in SPS. Subcutaneous immunoglobulin may be also an option in patients with poor venous access, or when there is a demonstrable early wearing-off effect, ensuring a more sustained benefit. Plasmapheresis has been of limited

and transient benefit and we do not routinely use it in spite of some anecdotal case reports.¹¹⁷ Corticosteroids are surprisingly ineffective in our experience with a large number of patients, although one anecdotal report had shown limited benefit.¹¹⁸ Furthermore, triggering or exacerbating diabetes is a serious consideration that further limits its use. Of paramount importance is the control of diabetes, which requires insulin most times and, if uncontrolled, seems to worsen the neurologic symptomatology.

Immunosuppressive agents such as azathioprine, methotrexate, cyclophosphamide and mycophenolate mofetil are equally disappointing, in spite of rare anecdotal reports.^{119,120} The most useful drug in this category is rituximab. A randomized controlled trial⁸⁶ we conducted in patients with SPS demonstrated lack of efficacy of rituximab compared with placebo owing to a strong placebo effect. In this series, however, seven patients improved and four of them with severe disease demonstrated meaningful to impressive improvements. On this basis, we believe rituximab is a useful drug for a subset of patients who have failed therapies with GABA-enhancing drugs and IVIg. It should be stressed that anti-GAD

antibody titers may drop but not to a statistically significant level and the titers do not correlate or predict improvement.

Some SPS patients who failed conventional immunosuppressive therapy have experienced benefit after autologous hematopoietic stem cell transplantation (auto-HSCT). In one small study, three patients with SPS and one with PERM were initially treated with cyclophosphamide (Cy) 2 g/m² + Granulocyte-colony stimulating factors (G-CSF) and then conditioned with Cy 200 mg/kg + Anti-thymocyte Globulin (ATG) followed by auto-HSCT. All patients tolerated the procedure well and showed improved physical performance. One patient's walking distance improved from 300 meters to 5 miles and one other's ambulation improved from being confined to a wheelchair to being able to walk with a frame. Two patients became seronegative for anti-GAD antibodies and normalized their neurophysiological abnormalities. Additional studies have also shown some benefit. Although auto-HSCT was thought promising, a large study aiming at 40 patients was terminated early after recruiting 23 patients because of lack of efficacy or transient benefits, taking into account potential serious complications.^{121,122} One of the many limitations of this study, as pointed out,¹²³ was the enrollment of patients with advanced disease. A new Hematopoietic Stem Cell Transplantation (HSMT) trial in SPS patients unresponsive to the therapies mentioned above might be, however, considered for patients with still early disease, in a controlled trial design taking into account a strong placebo effect, and the use of objective validated scales.¹²³

Therapy for the other, non-SPS, GAD-SDs

Therapeutic agents in autoimmune epilepsy, nystagmus and cerebellar disease are the same in the other GAD-SDs as those discussed in SPS, except if their manifestation is acute or subacute, as seen in autoimmune encephalitis. In these circumstances, we start with intravenous steroids 1000 mg daily for 5 days, followed by IVIg and rituximab, as needed. Anti-epileptics are added in patients with epilepsy, although GAD-associated epilepsy is reported refractory to the above immunomodulatory therapies, often requiring more aggressive immunosuppressive approaches, with mycophenolate mofetil or rituximab.⁵⁹ Interestingly, exogenous testosterone replacement therapy has been shown to reduce seizure frequency and intensity.¹²⁴ In some cases,

epilepsy surgery should be considered, although few beneficial surgical outcomes in GAD-associated epilepsy patients have been reported.⁵⁹ Patients with longer-standing disease and those with cerebellar ataxia, dysarthria and dysphagia have overall less impressive response to applied therapies.

Conclusion

The review highlights that high-titer anti-GAD antibodies are associated with an array of distinct neurological syndromes including SPS, cerebellar ataxia, epilepsy, limbic encephalitis, abnormal eye movements. Although high anti-GAD antibodies in serum or their presence in CSF are important for diagnosis, the titers do not correlate with disease severity and do not generally predict response to immunotherapy. Despite considerable efforts, using both *in vitro* and *in vivo* preparations, the pathophysiological role of anti-GAD antibodies has not yet been clarified, suggesting that other autoantibodies affecting inhibitory neurotransmission might be of importance, because autoimmunity targeting inhibitory synaptic antigens point to a unifying theme of hyperexcitability as the underlying pathomechanism.

Conflict of interest statement

The authors declare that there is no conflict of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD

Marinos C. Dalakas  <https://orcid.org/0000-0001-7070-1134>

References

1. Grimaldi LM, Martino G, Braghi S, *et al.* Heterogeneity of autoantibodies in stiff-man syndrome. *Ann Neurol* 1993; 34: 57–64.
2. Solimena M, Folli F, Denis-Donini S, *et al.* Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. *N Engl J Med* 1988; 318: 1012–1020.
3. Gresa-Arribas N, Ariño H, Martínez-Hernández E, *et al.* Antibodies to inhibitory synaptic proteins in neurological syndromes associated

- with glutamic acid decarboxylase autoimmunity. *PLoS One* 2015; 10: e0121364.
4. Ali F, Rowley M, Jayakrishnan B, *et al.* Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies. *J Autoimmun* 2011; 37: 79–87.
 5. Moersch FP and Woltman HW. Progressive fluctuating muscular rigidity and spasm (“stiff-man” syndrome); report of a case and some observations in 13 other cases. *Proc Staff Meet Mayo Clin* 1956; 31: 421–427.
 6. Dalakas MC, Fujii M, Li M, *et al.* The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. *Neurology* 2000; 55: 1531–1535.
 7. Alexopoulos H and Dalakas MC. A critical update on the immunopathogenesis of stiff person syndrome. *Eur J Clin Invest* 2010; 40: 1018–1025.
 8. Barker RA, Revesz T, Thom M, *et al.* Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. *J Neurol Neurosurg Psychiatry* 1998; 65: 633–640.
 9. Ameli R, Snow J, Rakocevic G, *et al.* A neuropsychological assessment of phobias in patients with stiff person syndrome. *Neurology* 2005; 64: 1961–1963.
 10. Mitsumoto H, Schwartzman MJ, Estes ML, *et al.* Sudden death and paroxysmal autonomic dysfunction in stiff-man syndrome. *J Neurol* 1991; 238: 91–96.
 11. Meinck HM, Ricker K and Conrad B. The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine. *J Neurol Neurosurg Psychiatry* 1984; 47: 280–287.
 12. Sandbrink F, Syed NA, Fujii MD, *et al.* Motor cortex excitability in stiff-person syndrome. *Brain* 2000; 123: 2231–2239.
 13. Levy LM, Dalakas MC and Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. *Ann Intern Med* 1999; 131: 522–530.
 14. Alexopoulos H and Dalakas MC. Immunology of stiff person syndrome and other GAD-associated neurological disorders. *Expert Rev Clin Immunol* 2013; 9: 1043–1053.
 15. Dinkel K, Meinck HM, Jury KM, *et al.* Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. *Ann Neurol* 1998; 44: 194–201.
 16. Levy LM, Levy-Reis I, Fujii M, *et al.* Brain gamma-aminobutyric acid changes in stiff-person syndrome. *Arch Neurol* 2005; 62: 970–974.
 17. Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. *Curr Treat Options Neurol* 2009; 11: 102–110.
 18. Ehler E, Latta J, Mandysová P, *et al.* Stiff-person syndrome following tick-borne meningoencephalitis. *Acta Medica (Hradec Kralove)* 2011; 54: 170–174.
 19. Raju R, Rakocevic G, Chen Z, *et al.* Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. *Brain* 2006; 129: 3270–3276.
 20. Rakocevic G, Alexopoulos H and Dalakas MC. Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder. *BMC Neurol* 2019; 19: 1.
 21. Mas N, Saiz A, Leite MI, *et al.* Antiglycine-receptor encephalomyelitis with rigidity. *J Neurol Neurosurg Psychiatry* 2011; 82: 1399–1401.
 22. Iizuka T, Leite MI, Lang B, *et al.* Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations. *J Neurol* 2012; 259: 1566–1573.
 23. De Camilli P, Thomas A, Cofield R, *et al.* The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. *J Exp Med* 1993; 178: 2219–2223.
 24. Folli F, Solimena M, Cofield R, *et al.* Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. *N Engl J Med* 1993; 328: 546–551.
 25. Butler MH, Hayashi A, Ohkoshi N, *et al.* Autoimmunity to gephyrin in stiff-man syndrome. *Neuron* 2000; 26: 307–312.
 26. Dalakas MC. Progress and stiff challenges in understanding the role of GAD-antibodies in stiff-person syndrome. *Exp Neurol* 2013; 247: 303–307.
 27. Saiz A, Arpa J, Sagasta A, *et al.* Autoantibodies to glutamic acid decarboxylase in three patients

- with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. *Neurology* 1997; 49: 1026–1030.
28. Honnorat J, Saiz A, Giometto B, *et al.* Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. *Arch Neurol* 2001; 58: 225–230.
 29. Iwasaki H, Sato R, Shichiri M, *et al.* A patient with type 1 diabetes mellitus and cerebellar ataxia associated with high titer of circulating anti-glutamic acid decarboxylase antibodies. *Endocr J* 2001; 48: 261–268.
 30. Bayreuther C, Hieronimus S, Ferrari P, *et al.* Auto-immune cerebellar ataxia with anti-GAD antibodies accompanied by de novo late-onset type 1 diabetes mellitus. *Diabetes Metab* 2008; 34: 386–388.
 31. Kong MF, Glibert G, Baleanu F, *et al.* Progressive cerebellar ataxia and new-onset diabetes. *Lancet* 2014; 383: 186.
 32. Saiz A, Blanco Y, Sabater L, *et al.* Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. *Brain* 2008; 131: 2553–2563.
 33. Hadjivassiliou M, Boscolo S, Tongiorgi E, *et al.* Cerebellar ataxia as a possible organ-specific autoimmune disease. *Mov Disord* 2008; 23: 1370–1377.
 34. Mitoma H, Adhikari K, Aeschlimann D, *et al.* Consensus paper: neuroimmune mechanisms of cerebellar ataxias. *Cerebellum* 2016; 15: 213–232.
 35. Manto M, Honnorat J, Hampe CS, *et al.* Disease-specific monoclonal antibodies targeting glutamate decarboxylase impair GABAergic neurotransmission and affect motor learning and behavioral functions. *Front Behav Neurosci* 2015; 9: 78.
 36. Ishikawa T, Kakei S and Mitoma H. Overlooked Holmes' clinical signs: reevaluation by recent physiological findings. *Cerebellum Ataxias* 2015; 2: 13.
 37. Ishikawa T, Tomatsu S, Tsunoda Y, *et al.* Releasing dentate nucleus cells from Purkinje cell inhibition generates output from the cerebrotocerebellum. *PLoS One* 2014; 9: e108774.
 38. Manto MU, Laute MA, Aguera M, *et al.* Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. *Ann Neurol* 2007; 61: 544–551.
 39. Manto MU, Hampe CS, Rogemond V, *et al.* Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia. *Orphanet J Rare Dis* 2011; 6: 3.
 40. Ben Taib NO, Manto M, Pandolfo M, *et al.* Hemicerebellectomy blocks the enhancement of cortical motor output associated with repetitive somatosensory stimulation in the rat. *J Physiol* 2005; 567: 293–300.
 41. Piccolo G, Tavazzi E, Cavallaro T, *et al.* Clinico-pathological findings in a patient with progressive cerebellar ataxia, autoimmune polyendocrine syndrome, hepatocellular carcinoma and anti-GAD autoantibodies. *J Neurol Sci* 2010; 290: 148–149.
 42. Ishida K, Mitoma H, Wada Y, *et al.* Selective loss of Purkinje cells in a patient with anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia. *J Neurol Neurosurg Psychiatry* 2007; 78: 190–192.
 43. Ishida K, Mitoma H and Mizusawa H. Reversibility of cerebellar GABAergic synapse impairment induced by anti-glutamic acid decarboxylase autoantibodies. *J Neurol Sci* 2008; 271: 186–190.
 44. Rakocevic G, Raju R, Semino-Mora C, *et al.* Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. *Neurology* 2006; 67: 1068–1070.
 45. Giometto B, Nicolao P, Macucci M, *et al.* Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase autoantibodies. *Lancet* 1998; 352: 457.
 46. Bien CG and Scheffer IE. Autoantibodies and epilepsy. *Epilepsia* 2011; 52(Suppl. 3): 18–22.
 47. Kwan P, Sills GJ, Kelly K, *et al.* Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study. *Epilepsy Res* 2000; 42: 191–195.
 48. Elisak M, Krysl D, Hanzalova J, *et al.* The prevalence of neural antibodies in temporal lobe epilepsy and the clinical characteristics of seropositive patients. *Seizure* 2018; 63: 1–6.
 49. Mäkelä KM, Hietaharju A, Brander A, *et al.* Clinical management of epilepsy with glutamic acid decarboxylase antibody positivity: the interplay between immunotherapy and anti-epileptic drugs. *Front Neurol* 2018; 9: 579.
 50. Quek AM, Britton JW, McKeon A, *et al.* Autoimmune epilepsy: clinical characteristics and response to immunotherapy. *Arch Neurol* 2012; 69: 582–593.
 51. Errichiello L, Perruolo G, Pascarella A, *et al.* Autoantibodies to glutamic acid decarboxylase

- (GAD) in focal and generalized epilepsy: a study on 233 patients. *J Neuroimmunol* 2009; 211: 120–123.
52. Peltola J, Kulmala P, Isojärvi J, *et al.* Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. *Neurology* 2000; 55: 46–50.
 53. Falip M, Carreño M, Miró J, *et al.* Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. *Eur J Neurol* 2012; 19: 827–833.
 54. Falip M, Rodriguez-Bel L, Castañer S, *et al.* Musicogenic reflex seizures in epilepsy with glutamic acid decarboxylase antibodies. *Acta Neurol Scand* 2018; 137: 272–276.
 55. Jesus-Ribeiro J, Bozorgi A, Alkhaldi M, *et al.* Autoimmune musicogenic epilepsy associated with anti-glutamic acid decarboxylase antibodies and stiff-person syndrome. *Clin Case Rep* 2020; 8: 61–64.
 56. Suleiman J, Brilot F, Lang B, *et al.* Autoimmune epilepsy in children: case series and proposed guidelines for identification. *Epilepsia* 2013; 54: 1036–1045.
 57. Carreño M, Bien CG, Asadi-Pooya AA, *et al.* Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. *Epilepsy Res* 2017; 129: 101–105.
 58. Waterhouse NJ, Sutton VR, Sedelies KA, *et al.* Cytotoxic T lymphocyte-induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis. *J Cell Biol* 2006; 173: 133–144.
 59. Daif A, Lukas RV, Issa NP, *et al.* Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. *Epilepsy Behav* 2018; 80: 331–336.
 60. Kanter IC, Huttner HB, Staykov D, *et al.* Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. *Epilepsia* 2008; 49: 914–920.
 61. Dalakas MC, Li M, Fujii M, *et al.* Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. *Neurology* 2001; 57: 780–784.
 62. Balint B, Jarius S, Nagel S, *et al.* Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. *Neurology* 2014; 82: 1521–1528.
 63. Gultekin SH, Rosenfeld MR, Voltz R, *et al.* Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. *Brain* 2000; 123: 1481–1494.
 64. Graus F, Titulaer MJ, Balu R, *et al.* A clinical approach to diagnosis of autoimmune encephalitis. *Lancet Neurol* 2016; 15: 391–404.
 65. Malter MP, Helmstaedter C, Urbach H, *et al.* Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. *Ann Neurol* 2010; 67: 470–478.
 66. Campbell AM and Garland H. Subacute myoclonic spinal neuronitis. *J Neurol Neurosurg Psychiatry* 1956; 19: 268–274.
 67. Carvajal-González A, Leite MI, Waters P, *et al.* Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. *Brain* 2014; 137: 2178–2192.
 68. McKeon A, Martinez-Hernandez E, Lancaster E, *et al.* Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. *JAMA Neurol* 2013; 70: 44–50.
 69. Alexopoulos H, Akrivou S and Dalakas MC. Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. *Neurology* 2013; 81: 1962–1964.
 70. Hinson SR, Lopez-Chiriboga AS, Bower JH, *et al.* Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders. *Neurol Neuroimmunol Neuroinflamm* 2018; 5: e438.
 71. Witherick J, Highley JR and Hadjivassiliou M. Pathological findings in a case of stiff person syndrome with anti-GAD antibodies. *Mov Disord* 2011; 26: 2138–2139.
 72. Takenoshita H, Shizuka-Ikeda M, Mitoma H, *et al.* Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia. *J Neurol Neurosurg Psychiatry* 2001; 70: 386–389.
 73. Antonini G, Nemni R, Giubilei F, *et al.* Autoantibodies to glutamic acid decarboxylase in downbeat nystagmus. *J Neurol Neurosurg Psychiatry* 2003; 74: 998–999.
 74. Ances BM, Dalmau JO, Tsai J, *et al.* Downbeating nystagmus and muscle spasms in a patient with glutamic-acid decarboxylase antibodies. *Am J Ophthalmol* 2005; 140: 142–144.
 75. Zivotofsky AZ, Siman-Tov T, Gadoth N, *et al.* A rare saccade velocity profile in stiff-person syndrome with cerebellar degeneration. *Brain Res* 2006; 1093: 135–140.

76. Pierrot-Deseilligny C and Milea D. Vertical nystagmus: clinical facts and hypotheses. *Brain* 2005; 128: 1237–1246.
77. Baizabal-Carvalho JF and Alonso-Juarez M. Vertical nystagmus associated with glutamic acid decarboxylase antibodies responding to cyclophosphamide. *J Neuroimmunol* 2018; 317: 5–7.
78. Markakis I, Alexiou E, Xifaras M, *et al.* Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase. *Clin Neurol Neurosurg* 2008; 110: 619–621.
79. Laroumagne S, Elharrar X, Coiffard B, *et al.* “Dancing eye syndrome” secondary to opsoclonus-myoclonus syndrome in small-cell lung cancer. *Case Rep Med* 2014; 2014: 545490.
80. Walikonis JE and Lennon VA. Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. *Mayo Clin Proc* 1998; 73: 1161–1166.
81. McKeon A and Tracy JA. GAD65 neurological autoimmunity. *Muscle Nerve* 2017; 56: 15–27.
82. Budhram A, Sechi E, Flanagan EP, *et al.* Clinical spectrum of high-titre GAD65 antibodies. *J Neurol Neurosurg Psychiatry*. Epub ahead of print 9 February 2021. DOI: 10.1136/jnnp-2020-325275.
83. Muñoz-Lopetegi A, de Bruijn MAAM, Boukhrissi S, *et al.* Neurologic syndromes related to anti-GAD65: clinical and serologic response to treatment. *Neurol Neuroimmunol Neuroinflamm* 2020; 7: e696.
84. Dimitriadou MM, Alexopoulos H, Akrivou S, *et al.* Anti-neuronal antibodies within the IVIg preparations: importance in clinical practice. *Neurotherapeutics* 2020; 17: 235–242.
85. Dalakas MC, Fujii M, Li M, *et al.* High-dose intravenous immune globulin for stiff-person syndrome. *N Engl J Med* 2001; 345: 1870–1876.
86. Dalakas MC, Rakocevic G, Dambrosia JM, *et al.* A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. *Ann Neurol* 2017; 82: 271–277.
87. Chéramy M, Hampe CS, Ludvigsson J, *et al.* Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals. *Clin Exp Immunol* 2013; 171: 247–254.
88. Erlander MG, Tillakaratne NJ, Feldblum S, *et al.* Two genes encode distinct glutamate decarboxylases. *Neuron* 1991; 7: 91–100.
89. Fenalti G, Law RH, Buckle AM, *et al.* GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop. *Nat Struct Mol Biol* 2007; 14: 280–286.
90. Patel AB, de Graaf RA, Martin DL, *et al.* Evidence that GAD65 mediates increased GABA synthesis during intense neuronal activity in vivo. *J Neurochem* 2006; 97: 385–396.
91. Uibo R and Lernmark A. GAD65 autoimmunity-clinical studies. *Adv Immunol* 2008; 100: 39–78.
92. Raju R, Foote J, Banga JP, *et al.* Analysis of GAD65 autoantibodies in stiff-person syndrome patients. *J Immunol* 2005; 175: 7755–7762.
93. Vianello M, Keir G, Giometto B, *et al.* Antigenic differences between neurological and diabetic patients with anti-glutamic acid decarboxylase antibodies. *Eur J Neurol* 2005; 12: 294–299.
94. Fenalti G, Hampe CS, Arafat Y, *et al.* COOH-terminal clustering of autoantibody and T-cell determinants on the structure of GAD65 provide insights into the molecular basis of autoreactivity. *Diabetes* 2008; 57: 1293–1301.
95. Law RH, Rowley MJ, Mackay IR, *et al.* Expression in *Saccharomyces cerevisiae* of antigenically and enzymatically active recombinant glutamic acid decarboxylase. *J Biotechnol* 1998; 61: 57–68.
96. Jayakrishnan B, Hoke DE, Langendorf CG, *et al.* An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes. *PLoS One* 2011; 6: e18411.
97. Butler MH, Solimena M, Dirx R Jr, *et al.* Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. *J Exp Med* 1993; 178: 2097–2106.
98. Al-Bukhari TA, Radford PM, Bouras G, *et al.* Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis. *Clin Exp Immunol* 2002; 130: 131–139.
99. Kim J, Namchuk M, Bugawan T, *et al.* Higher autoantibody levels and recognition of a linear NH₂-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. *J Exp Med* 1994; 180: 595–606.
100. Piquer S, Belloni C, Lampasona V, *et al.* Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association. *Clin Immunol* 2005; 117: 31–35.

101. Ziegler B, Schlosser M, Lühder F, *et al.* Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and stiff-man syndrome. *Acta Diabetol* 1996; 33: 225–231.
102. Liimatainen S, Honnorat J, Pittock SJ, *et al.* GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies. *Orphanet J Rare Dis* 2018; 13: 55.
103. Fouka P, Alexopoulos H, Akrivou S, *et al.* GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders. *J Neuroimmunol* 2015; 281: 73–77.
104. Graus F, Saiz A and Dalmau J. GAD antibodies in neurological disorders - insights and challenges. *Nat Rev Neurol* 2020; 16: 353–365.
105. Hansen N, Grünewald B, Weishaupt A, *et al.* Human stiff person syndrome IgG-containing high-titer anti-GAD65 autoantibodies induce motor dysfunction in rats. *Exp Neurol* 2013; 239: 202–209.
106. Chang T, Alexopoulos H, McMenamin M, *et al.* Neuronal surface and glutamic acid decarboxylase autoantibodies in nonparaneoplastic stiff person syndrome. *JAMA Neurol* 2013; 70: 1140–1149.
107. Hackert JK, Müller L, Rohde M, *et al.* Anti-GAD65 containing cerebrospinal fluid does not alter GABAergic transmission. *Front Cell Neurosci* 2016; 10: 130.
108. Stemmler N, Rohleder K, Malter MP, *et al.* Serum from a patient with GAD65 antibody-associated limbic encephalitis did not alter GABAergic neurotransmission in cultured hippocampal networks. *Front Neurol* 2015; 6: 189.
109. Sommer C, Weishaupt A, Brinkhoff J, *et al.* Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. *Lancet* 2005; 365: 1406–1411.
110. Geis C, Grünewald B, Weishaupt A, *et al.* Human IgG directed against amphiphysin induces anxiety behavior in a rat model after intrathecal passive transfer. *J Neural Transm (Vienna)* 2012; 119: 981–985.
111. Vianello M, Bisson G, Dal Maschio M, *et al.* Increased spontaneous activity of a network of hippocampal neurons in culture caused by suppression of inhibitory potentials mediated by anti-gad antibodies. *Autoimmunity* 2008; 41: 66–73.
112. Ishida K, Mitoma H, Song SY, *et al.* Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. *Ann Neurol* 1999; 46: 263–267.
113. Mitoma H, Song SY, Ishida K, *et al.* Presynaptic impairment of cerebellar inhibitory synapses by an autoantibody to glutamate decarboxylase. *J Neurol Sci* 2000; 175: 40–44.
114. Soler H, Dorca-Arévalo J, González M, *et al.* The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy. *Neurobiol Aging* 2017; 49: 40–51.
115. Thaler FS, Thaller AL, Biljecki M, *et al.* Abundant glutamic acid decarboxylase (GAD)-reactive B cells in gad-antibody-associated neurological disorders. *Ann Neurol* 2019; 85: 448–454.
116. Burton AR, Baquet Z, Eisenbarth GS, *et al.* Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+ T cells. *J Immunol* 2010; 184: 4863–4870.
117. Vasconcelos OM and Dalakas MC. Stiff-person syndrome. *Curr Treat Options Neurol* 2003; 5: 79–90.
118. Dalakas MC. Advances in the pathogenesis and treatment of patients with stiff person syndrome. *Current Neurology and Neuroscience Reports* 2008; 8: 48–55.
119. Hao W, Davis C, Hirsch IB, *et al.* Plasmapheresis and immunosuppression in stiff-man syndrome with type 1 diabetes: a 2-year study. *J Neurol* 1999; 246: 731–735.
120. Baker MR, Das M, Isaacs J, *et al.* Treatment of stiff person syndrome with rituximab. *J Neurol Neurosurg Psychiatry* 2005; 76: 999–1001.
121. Kass-Iliyya L, Snowden JA, Thorpe A, *et al.* Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience. *J Neurol*. Epub ahead of print 12 August 2020. DOI: 10.1007/s00415-020-10054-8.
122. Burt RK, Balabanov R, Han X, *et al.* Autologous hematopoietic stem cell transplantation for stiff person spectrum disorder: a clinical trial. *Neurology*. Epub ahead of print 14 December 2020. DOI: 10.1212/WNL.0000000000011338.
123. Dalakas MC. A Hsct trial in stiff person syndrome: limited benefits halt enrollment but should be more to come? *Neurology*. Epub ahead of print 14 December 2020. DOI: 10.1212/WNL.0000000000011349.
124. Heiry M, Afra P, Matsuo F, *et al.* Improvement of GAD65-associated autoimmune epilepsy with testosterone replacement therapy. *Neurol Neuroimmunol Neuroinflamm* 2015; 2: e142.